Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Finerenone: intervention A · 1 trial · 2 indications
Cmax: maximum concentration.
AUC = area under the curve, which was the total amount of finerenone in plasma
| Arm | Type | Description |
|---|---|---|
| finerenone sequences: intervention A_intervention B | EXPERIMENTAL | Participants received intervention A first, with a washout period of at least 72 hours, participants then received intervention B |
| finerenone sequences: intervention B_intervention A | EXPERIMENTAL | Participants received intervention B first, with a washout period of at least 72 hours, participants then received intervention A |
| Name | Type | Description |
|---|---|---|
| Finerenone (BAY94-8862): intervention A | DRUG | Study intervention A: one tablet of dose strength 1 one tablet of dose strength 1 = two tablets of dose strength 2 |
| Finerenone (BAY94-8862): intervention B | DRUG | Study intervention B: two tablets of dose strength 2 two tablets of dose strength 2 = one tablet of dose strength 1 |
Inclusion Criteria: * Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent. * Participants who were overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, body temperature, vital signs, and E...
Finerenone is a small molecule being studied for heart failure with left ventricular ejection fraction greater than or equal to 40 per cent. It is developed by Bayer AG (ticker: BAYRY) and is currently in Phase 1 clinical development as an investigational therapy.
Finerenone is a small molecule being developed by Bayer AG for cardiovascular conditions. The specific molecular target has not been disclosed in the available clinical trial information, so its mechanism of action is not detailed here.
Finerenone is developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. The drug is currently in Phase 1 clinical development for heart failure with left ventricular ejection fraction greater than or equal to 40 per cent.
Finerenone is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 60 participants.
Finerenone has one completed clinical trial, NCT07116512, a Phase 1 study in healthy male participants in Germany. The trial compared how much finerenone gets into the blood when the same amount is taken in one versus two tablets of different strengths.
Finerenone is also referred to as intervention A in clinical trial documentation. The drug is being studied under the name Finerenone, with intervention A serving as an alternative label in the study context.